Related Experiment Video
Updated: Jul 10, 2026
05:55
Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
Published on: September 27, 2024
[Glucocorticoid-induced osteoporosis].
Lucyna Papierska1, Michał Rabijewski
1Klinika Endokrynologii, Centrum Medyczne Kształcenia Podyplomowego, Warszawa. lucyferysia@wp.pl
Polskie Archiwum Medycyny Wewnetrznej
|November 21, 2007
Summary
Long-term glucocorticoid use can cause osteoporosis and increase fracture risk, even with mild bone density loss. Early intervention with bone-protective agents is crucial for patients on steroids.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Context:
- Glucocorticoid therapy, common for various conditions, is associated with significant skeletal complications.
- Osteoporosis is a frequent issue in patients receiving prednisone doses of 7.5 mg or more daily for over three months.
Purpose:
- To highlight the high fracture risk in glucocorticoid-induced osteoporosis (GIOP) that may not be predicted by bone mineral density (BMD) alone.
- To emphasize the need for early initiation of antifracture therapy in patients on long-term glucocorticoids.
Summary:
- Prolonged glucocorticoid use inhibits bone formation and increases resorption, leading to negative calcium balance and secondary hyperparathyroidism.
- Patients may develop osteomalacia and avascular necrosis, with fracture risk exceeding that suggested by BMD assessments.
- A T-score of -1.5 indicates the need for antifracture treatment, starting with calcium and vitamin D supplementation.
Impact:
- Early treatment with agents like bisphosphonates (alendronate, risedronate), hormone therapy, or anabolic agents can effectively prevent fractures in at-risk patients.
- This understanding guides clinical practice towards proactive management of skeletal health in patients undergoing long-term glucocorticoid treatment.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Cushing Syndrome I: Introduction
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...